CN104789555A - Method of expressing regulatory element based on evolution gene by synthesizing single-chain DNA library - Google Patents
Method of expressing regulatory element based on evolution gene by synthesizing single-chain DNA library Download PDFInfo
- Publication number
- CN104789555A CN104789555A CN201510212921.9A CN201510212921A CN104789555A CN 104789555 A CN104789555 A CN 104789555A CN 201510212921 A CN201510212921 A CN 201510212921A CN 104789555 A CN104789555 A CN 104789555A
- Authority
- CN
- China
- Prior art keywords
- primer
- mutant
- strand
- library
- template
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 42
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 40
- 230000001105 regulatory effect Effects 0.000 title abstract description 6
- 230000002194 synthesizing effect Effects 0.000 title abstract description 3
- 230000035772 mutation Effects 0.000 claims abstract description 35
- 238000005516 engineering process Methods 0.000 claims abstract description 27
- 238000000338 in vitro Methods 0.000 claims abstract description 17
- 108020004414 DNA Proteins 0.000 claims description 42
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 102000053602 DNA Human genes 0.000 claims description 18
- 238000011144 upstream manufacturing Methods 0.000 claims description 17
- 108020004682 Single-Stranded DNA Proteins 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 9
- 108010061982 DNA Ligases Proteins 0.000 claims description 8
- 102000012410 DNA Ligases Human genes 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 230000003321 amplification Effects 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000033228 biological regulation Effects 0.000 claims description 4
- 238000013461 design Methods 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 108091008146 restriction endonucleases Proteins 0.000 claims description 2
- 239000003513 alkali Substances 0.000 claims 2
- 238000002703 mutagenesis Methods 0.000 claims 2
- 231100000350 mutagenesis Toxicity 0.000 claims 2
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- 230000029087 digestion Effects 0.000 claims 1
- 230000013011 mating Effects 0.000 claims 1
- 238000010353 genetic engineering Methods 0.000 abstract description 4
- 238000013537 high throughput screening Methods 0.000 abstract description 4
- 239000013604 expression vector Substances 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 59
- 108090000790 Enzymes Proteins 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 11
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 11
- 230000008569 process Effects 0.000 description 9
- 230000037361 pathway Effects 0.000 description 8
- 238000005215 recombination Methods 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 239000011535 reaction buffer Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000010586 diagram Methods 0.000 description 4
- 108010063905 Ampligase Proteins 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 101150076849 rpoS gene Proteins 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010068051 Chimerism Diseases 0.000 description 2
- 108060002716 Exonuclease Proteins 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 108010011035 endodeoxyribonuclease DpnI Proteins 0.000 description 2
- 102000013165 exonuclease Human genes 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000012269 metabolic engineering Methods 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 125000006850 spacer group Chemical group 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 230000037429 base substitution Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000011942 biocatalyst Substances 0.000 description 1
- 239000002551 biofuel Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000009088 enzymatic function Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种基于合成单链DNA文库进化基因表达调控元件的方法,属于基因工程技术领域。The invention relates to a method for evolving gene expression regulation elements based on a synthetic single-stranded DNA library, and belongs to the technical field of genetic engineering.
背景技术Background technique
随着分子生物学技术和基因工程技术的发展,已有数千种类的天然酶基因被发现,由于酶介导的生物催化具有环境友好型,高效专一性和反应条件温和等优点,作为生催化的主导者,被广泛应用于复杂的药物、中间体、化合物的合成,甚至生物燃料的合成。合成生物和代谢工程中酶是核心的参与者,通过构建一系列的代谢合成途径,可以实现微生物代谢合成各种有机合成无法获得的复杂化合物,如芳烃、碳水化合物、有机酸、醇和其他次级代谢产物。然而,在大多数情况中,天然酶的性质的局限性,极大地限制了它在各种复杂条件下的使用。With the development of molecular biology technology and genetic engineering technology, thousands of natural enzyme genes have been discovered. Because enzyme-mediated biocatalysis has the advantages of environmental friendliness, high efficiency and specificity, and mild reaction conditions, it is used as a biocatalyst. The leader of catalysis is widely used in the synthesis of complex drugs, intermediates, compounds, and even the synthesis of biofuels. Enzymes are the core participants in synthetic biology and metabolic engineering. By constructing a series of metabolic synthesis pathways, microorganisms can metabolize and synthesize various complex compounds that cannot be obtained by organic synthesis, such as aromatic hydrocarbons, carbohydrates, organic acids, alcohols and other secondary metabolite. However, in most cases, limitations in the properties of natural enzymes greatly limit their use in a variety of complex conditions.
自然界在遗传突变与自然选择的动态平衡过程中,进化出了非常精确且又高效的酶,然而自然选择的速度非常缓慢,需要漫长的时间。人们迫切需要对天然酶进行人工进化和改造,以期获得能够满足人们需求的功能更强大的新酶。在当今实验技术条件下,人们通过物理化学等方法,例如紫外、射线和亚硝酸盐等极大地提高了基因突变的频率,为人工快速进化基因提供了可能。然而,物理化学等方法造成的突变往往都是有害突变,且随机性较大,还无法满足大规模的进化需求。随着分子生物学技术的日趋成熟,从基因操作水平上直接对天然基因引入特定的或随机的突变位点已成为可能。随机突变方法是通过引进随机的碱基替换,进而筛选理想的突变体。例如易错PCR技术,是目前使用较广的基因进化方式之一,通过在体外聚合酶链反应(PCR)过程中随机引入突变点,高通量筛选有益进化的基因。经过多轮次操作后,可以获得酶学性质和功能发生明显变化的新酶。在此基础上发展起来的各种依赖PCR技术引入突变点进化基因的技术如定点突变、基因嵌合以及瞬时模板的随机嵌合等方法。然而,上述方法产生的突变点多样性少,产生的突变体也多为有害突变,工作量大而且效率极低。In the dynamic balance process of genetic mutation and natural selection, nature has evolved very precise and efficient enzymes, but the speed of natural selection is very slow and takes a long time. There is an urgent need for artificial evolution and modification of natural enzymes in order to obtain new enzymes with more powerful functions that can meet people's needs. Under the conditions of today's experimental technology, people have greatly increased the frequency of gene mutations through physical and chemical methods, such as ultraviolet light, radiation, and nitrite, providing the possibility for artificial rapid evolution of genes. However, the mutations caused by physical and chemical methods are often harmful mutations, and they are relatively random, which cannot meet the needs of large-scale evolution. With the maturity of molecular biology technology, it has become possible to directly introduce specific or random mutation sites into natural genes from the level of genetic manipulation. The random mutation method is to screen ideal mutants by introducing random base substitutions. For example, error-prone PCR technology is one of the most widely used gene evolution methods at present. Through the random introduction of mutation points in the in vitro polymerase chain reaction (PCR) process, high-throughput screening of genes beneficial to evolution is performed. After multiple rounds of operations, new enzymes with significant changes in enzymatic properties and functions can be obtained. Various technologies developed on this basis rely on PCR technology to introduce mutation point evolutionary genes, such as site-directed mutagenesis, gene chimerism, and random chimerism of transient templates. However, the mutation point diversity generated by the above method is small, and most of the mutants generated are harmful mutations, the workload is heavy and the efficiency is extremely low.
1994年,一种的定向进化新技术DNA改组(DNA shuffling)悄然诞生,Stemmer在Nature发表了一篇题为Rapid evolution of a p rotein in vitro by DNA shuffling的文章,首次提出了DNA改组技术。研究者以β-内酰胺酶系统为试验对象,运用DNA改组,经过三轮筛选和两次回交得到一新菌株,其头孢噻肟(cefotaxime)的最低抑制浓度比原始菌株提高了16000倍,远高于错误倾向PCR的突变筛选结果。随后发展起来的各种以重组技术为基础的方法,以提高基因杂交的程度和筛选效率为目标,都获得了比较好的效果。然而,DNA shuffling技术对序列同源性的要求较高(同源性大于75%)且需要获取同源基因材料。这两个条件极大限制了DNA shuffling技术的应用,同时该技术产生的突变体往往有较多的移码突变体。In 1994, a new technology of directed evolution, DNA shuffling, was quietly born. Stemmer published an article titled Rapid evolution of a protein in vitro by DNA shuffling in Nature, and proposed the DNA shuffling technology for the first time. The researchers took the β-lactamase system as the test object, used DNA shuffling, and obtained a new strain after three rounds of screening and two backcrosses. The minimum inhibitory concentration of cefotaxime was 16,000 times higher than that of the original strain, far Mutation screening results higher than error-prone PCR. Various methods based on recombination technology developed subsequently aimed at improving the degree of gene hybridization and screening efficiency, and achieved relatively good results. However, DNA shuffling technology requires high sequence homology (homology greater than 75%) and needs to obtain homologous genetic material. These two conditions greatly limit the application of DNA shuffling technology, and the mutants produced by this technology often have more frameshift mutants.
此外,当前合成生物学和代谢工程对合成途径的改造基本都注重在对合成途径基因的表达调控上,例如增强途径基因的表达,敲除或者抑制竞争途径,例如优化启动子或者核糖体结合位点,优化基因的密码子,改造途径基因的间隔调控区域等。另外,对合成途径中的酶进行改造也是非常有必要的,例如关键酶的限速问题、受产物或者底物反馈抑制。因为,如果仅仅加强表达水平,可能会导致细胞合成能力的浪费和细胞生长负担,而不能从根本上解决代谢途径流量平衡的问题。In addition, the current modification of synthetic biology and metabolic engineering to synthetic pathways basically focuses on the expression regulation of synthetic pathway genes, such as enhancing the expression of pathway genes, knocking out or inhibiting competing pathways, such as optimizing promoters or ribosome binding sites Points, optimize the codons of genes, modify the spacer regulatory regions of pathway genes, etc. In addition, it is also very necessary to modify the enzymes in the synthetic pathway, such as the rate-limiting problem of key enzymes, feedback inhibition by products or substrates. Because, if only the expression level is enhanced, it may lead to the waste of cell synthesis capacity and the burden of cell growth, but cannot fundamentally solve the problem of metabolic pathway flow balance.
本发明采用体外PCR重组技术为基础,通过人工合成单链DNA文库,采用PCR技术获得含有多样性极其丰富的突变文库,再采用体外重组技术构建突变筛选文库。此技术克服了上述随机突变多样性不足、DNA shuffling技术同源序列和同源基因材料的限制等因素,而且操作实施简单,易于获得丰富的突变体文库,为基因体外快速进化奠定了基础,同时,结合蛋白结构生物信息学和合成生物学,特别适合于酶基因和代谢合成途径的快速定向进化应用。The invention adopts in vitro PCR recombination technology as the basis, artificially synthesizes a single-stranded DNA library, adopts PCR technology to obtain a mutation library with extremely rich diversity, and then uses in vitro recombination technology to construct a mutation screening library. This technology overcomes the aforementioned factors such as insufficient diversity of random mutations, limitations of DNA shuffling technology homologous sequences and homologous gene materials, etc., and is easy to operate and implement, and it is easy to obtain abundant mutant libraries, laying the foundation for the rapid evolution of genes in vitro, and at the same time , combined with protein structure bioinformatics and synthetic biology, especially suitable for rapid directed evolution applications of enzyme genes and metabolic synthetic pathways.
发明内容Contents of the invention
本发明提供了一种基于合成单链DNA文库进化基因表达调控元件的方法(RapidlyEfficient Combinatorial Oligonucleotides for Direct Evolution,RECODE),主要包括制备突变体文库,所述突变体文库包括单链突变体文库和双链突变体文库。单链突变体文库与双链突变体文库可以分步构建,也可以同步构建。为构建单链突变体文库,针对亲本基因的各个目标突变区域分别设计引物,各引物方向相同,并通过向PCR体系中添加DNA连接酶来连接各发生突变的核苷酸片段,得到完整的单链突变体;为构建双链突变体文库,单链突变体的两端需带上额外的锚点序列,便于在双链化时,设计用于特异性扩增单链突变体的引物。The present invention provides a method (Rapidly Efficient Combinatorial Oligonucleotides for Direct Evolution, RECODE) based on synthetic single-stranded DNA library evolution gene expression regulatory elements, mainly including the preparation of mutant library, the mutant library includes single-stranded mutant library and double Chain mutant library. The single-chain mutant library and the double-chain mutant library can be constructed step by step or simultaneously. In order to construct a single-stranded mutant library, primers were designed for each target mutation region of the parental gene. Strand mutants: In order to construct a double-stranded mutant library, the two ends of the single-stranded mutants need to carry additional anchor sequences to facilitate the design of primers for the specific amplification of single-stranded mutants when double-stranded.
所述目标突变区域可以是有目的地选择得到的或随机产生的。对一条链上进行同时突变的区域数量在理论上不受限制,实际操作中可根据需要自行设定,2k以内的基因可以在1-15个位点之间。The target mutation region can be purposefully selected or randomly generated. The number of regions for simultaneous mutation on a chain is not limited in theory, and can be set according to actual needs in practice. The number of genes within 2k can be between 1-15 sites.
所述方向相同,是指各引物均为3’至5’方向,或均为5’至3’方向。当亲本基因是双链DNA时,引物方向相同可以保证PCR过程仅以特定方向的DNA链为模板,最终得到单链突变体。The same direction means that each primer is in the 3' to 5' direction, or in the 5' to 3' direction. When the parental gene is double-stranded DNA, the same primer direction can ensure that the PCR process only uses the DNA strand in a specific direction as a template, and finally obtains a single-stranded mutant.
所述亲本基因编码的是启动子、核糖体结合位点或其他基因表达调控元件。亲本基因的存在形式不受限制,可以为质粒、基因组、双链DNA片段或者单链cDNA。The parental genes encode promoters, ribosome binding sites or other gene expression regulatory elements. The form of the parental gene is not limited, and may be a plasmid, genome, double-stranded DNA fragment or single-stranded cDNA.
所述单链突变体文库和双链突变体文库同步构建,是直接向构建单链突变体文库的PCR体系中添加特异结合单链突变体的引物,边PCR获得单链突变体,边以单链突变体为模板进行双链化反应和双链突变体的扩增反应。The synchronous construction of the single-stranded mutant library and the double-stranded mutant library is to directly add primers that specifically bind to single-stranded mutants to the PCR system for constructing the single-stranded mutant library, and obtain single-stranded mutants by PCR. The double-stranded mutant is used as a template for double-stranded reaction and double-stranded mutant amplification reaction.
所述单链突变体文库和双链突变体文库分步构建时,直接以含单链突变体文库的PCR混合物作为模板,不更换反应体系,直接向其中加入特异结合单链突变体的引物进行第二轮PCR制备全长完整的双链突变体;或者以经柱纯化回收后的单链突变体文库作为模板,重新配制反应体系进行第二轮PCR制备全长完整的双链突变体。When the single-stranded mutant library and the double-stranded mutant library are constructed step by step, the PCR mixture containing the single-stranded mutant library is directly used as a template, and the reaction system is not changed, and primers that specifically bind to the single-stranded mutant are directly added thereto. The second round of PCR prepares full-length and complete double-stranded mutants; or uses the single-stranded mutant library recovered after column purification as a template to reconstitute the reaction system for the second round of PCR to prepare full-length and complete double-stranded mutants.
为构建单链突变体文库,针对亲本基因的一个或多个目标突变区域,分别设计相应的引物,称为编辑引物。所述编辑引物含有需要向突变区域引入的突变碱基且3’和5’端分别有适当长度的与模板链匹配的序列;涉及多个突变区域时,各编辑引物为同方向,均与同一模板链配对结合。同时,合成两条与编辑引物同方向的锚点引物,其中一条是上游锚点引物,一条是下游锚点引物,所述上游锚点引物含有一段与模板链3’端匹配的核苷酸序列,此外,该上游锚点引物的5’端还有15-25bp的锚点序列;所述下游锚点引物含有一段与模板链5’端匹配的核苷酸序列,此外,该下游锚点引物的3’端还有15-25bp的锚点序列。To construct a single-stranded mutant library, corresponding primers are designed for one or more target mutation regions of the parental gene, called editing primers. The editing primers contain the mutated bases that need to be introduced into the mutated region, and the 3' and 5' ends have sequences matching the template strand of appropriate length; Template strands combine in pairs. At the same time, synthesize two anchor primers in the same direction as the editing primer, one of which is an upstream anchor primer and one is a downstream anchor primer, and the upstream anchor primer contains a nucleotide sequence that matches the 3' end of the template strand , In addition, the 5' end of the upstream anchor primer also has an anchor sequence of 15-25bp; the downstream anchor primer contains a nucleotide sequence that matches the 5' end of the template chain, in addition, the downstream anchor primer There is also a 15-25bp anchor sequence at the 3' end.
对于编辑引物,为节省合成费用,一般建议编辑引物长度低于59bp,若有需要可增加引物长度,或者可分为两条短引物。需要进行突变的位点一般置于编辑引物的中间部位,根据需要可进行高度简并,若亲本编码的是蛋白序列,为避免终止密码子TAA、TAG和TGA出现,三联密码子可简并为VNN或者降低终止子出现的概率,编辑引物合成优选PAGE纯化方式。For editing primers, in order to save synthesis costs, it is generally recommended that the length of editing primers be less than 59 bp, if necessary, the length of the primers can be increased, or it can be divided into two short primers. The site that needs to be mutated is generally placed in the middle of the editing primer, and can be highly degenerated as needed. If the parental code is a protein sequence, in order to avoid the occurrence of stop codons TAA, TAG and TGA, the triple codon can be degenerated as follows: VNN may reduce the probability of terminator occurrence, and editing primer synthesis is preferred for PAGE purification.
所述锚点引物,还可以兼具编辑引物的功能,即在作为锚点引物的同时,还可以含有需要向突变区域引入的突变碱基。The anchor primer can also function as an editing primer, that is, while serving as an anchor primer, it can also contain a mutated base that needs to be introduced into the mutated region.
所述锚点序列,一方面可以在构建双链突变体文库时,用于设计专一与单链突变体结合的外端引物,另一方面还可作为同源重组序列,用于突变体文库与表达载体的连接。在将双链突变体与载体连接时,不建议使用限制性酶切位点进行重组载体,因为高度简并的突变引入,可能会使基因内部出现相应的酶切位点。The anchor point sequence, on the one hand, can be used to design an outer primer specifically combined with a single-stranded mutant when constructing a double-stranded mutant library; on the other hand, it can also be used as a homologous recombination sequence for the mutant library Ligation to expression vectors. When linking double-stranded mutants to the vector, it is not recommended to use restriction enzyme sites for recombination vectors, because the introduction of highly degenerate mutations may cause corresponding enzyme sites to appear inside the gene.
所述需要在突变区域引入的突变碱基可以是具体的碱基序列,也可以是简并碱基序列。The mutated bases to be introduced in the mutated region may be a specific base sequence or a degenerate base sequence.
所述编辑引物和下游锚点引物,在使用前先采用T4多聚核苷酸激酶对引物的5’端羟基进行磷酸化反应。Before using the editing primer and the downstream anchor primer, T4 polynucleotide kinase is used to phosphorylate the 5' terminal hydroxyl of the primer.
所述编辑引物的3’和5’端序列分别保留15-30bp的与模板完全匹配的寡聚核苷酸序列。The 3' and 5' end sequences of the editing primers respectively retain 15-30 bp oligonucleotide sequences that completely match the template.
制备单链突变体文库的反应过程是DNA延伸和DNA连接同步进行的反应:上、下游锚点引物、编辑引物与模板DNA以适当摩尔比混合,添加DNA聚合酶和DNA连接酶,反应缓冲液。反应缓冲液中Mg2+浓度为1-10mM,PCR退火温度为40-66℃,PCR延伸温度为65-72℃,PCR反应循环数为1-35个。PCR产物中包括变性解链后未用作模板的单链DNA、大量的发生突变的单链DNA、与模板结合着的处于双链状态的发生突变的DNA链。The reaction process of preparing a single-stranded mutant library is a simultaneous reaction of DNA extension and DNA ligation: upstream and downstream anchor primers, editing primers and template DNA are mixed at an appropriate molar ratio, DNA polymerase and DNA ligase are added, and reaction buffer . The Mg 2+ concentration in the reaction buffer is 1-10mM, the PCR annealing temperature is 40-66°C, the PCR extension temperature is 65-72°C, and the number of PCR reaction cycles is 1-35. The PCR products include single-stranded DNA that is not used as a template after denaturation and melting, a large number of mutated single-stranded DNA, and mutated DNA strands that are in a double-stranded state combined with the template.
在本发明的一种实施方式中,制备单链突变体文库时,与模板链不同位置结合的引物的摩尔数相同。In one embodiment of the present invention, when preparing a single-stranded mutant library, the number of moles of primers that bind to different positions of the template strand is the same.
为构建双链突变体文库,可以以含单链突变体文库的PCR混合物或者经柱纯化回收后的单链突变体文库作为模板,进行第二轮PCR制备全长完整的双链突变体基因产物;或者直接向构建单链突变体文库的反应体系中添加特异结合单链突变体的引物,边PCR获得单链突变体边进行双链化反应和双链突变体的扩增反应(简称为一步PCR)。为构建双链突变体文库,以单链突变体为模板设计一对用于扩增单链突变体全长基因的外端引物,所述外端引物分别与锚点引物的锚点序列相匹配或相同。只有发生突变的带上锚点序列的单链DNA能与外端引物结合,因而扩增产物是双链突变体文库。制备好的PCR产物,纯化回收后,采用体外重组技术进行克隆,构建高通量筛选文库,筛选具备所需性质特征的突变子。To construct a double-stranded mutant library, the PCR mixture containing the single-stranded mutant library or the single-stranded mutant library recovered after column purification can be used as a template to perform a second round of PCR to prepare a full-length and complete double-stranded mutant gene product or directly add primers that specifically bind to single-stranded mutants in the reaction system for constructing single-stranded mutant libraries, and carry out double-strandization reactions and amplification reactions of double-stranded mutants (referred to as one-step for short) while obtaining single-stranded mutants by PCR. PCR). In order to construct a double-stranded mutant library, a pair of outer primers for amplifying the full-length gene of the single-stranded mutant is designed using the single-stranded mutant as a template, and the outer primers match the anchor sequences of the anchor primers respectively or the same. Only the mutated single-stranded DNA with the anchor sequence can combine with the outer primer, so the amplified product is a library of double-stranded mutants. After the prepared PCR products are purified and recovered, they are cloned using in vitro recombination technology to construct a high-throughput screening library to screen for mutants with the desired properties and characteristics.
所述以含单链突变体文库的PCR混合物或者经柱纯化回收后的单链突变体文库作为模板进行第二轮PCR制备全长完整的双链突变体基因产物时,只需经过少数循环,就能得到大量双链突变体。所述的单链突变体文库,在进行双链突变体文库的制备之前,可以采用DpnI限制性内切酶消化模板链。当然,即使不使用DpnI限制性内切酶降解模板DNA,在制备双链突变文库的PCR过程中,由于一对外端引物含有与锚点序列匹配的序列,而模板DNA不含有与锚点序列匹配的序列,因此,模板DNA并不会发生扩增。When the PCR mixture containing the single-stranded mutant library or the single-stranded mutant library recovered after column purification is used as a template for the second round of PCR to prepare a full-length complete double-stranded mutant gene product, only a few cycles are required. A large number of double-stranded mutants can be obtained. For the single-strand mutant library, before the double-strand mutant library is prepared, the template strand can be digested with DpnI restriction endonuclease. Of course, even if DpnI restriction endonuclease is not used to degrade the template DNA, during the PCR process of preparing the double-stranded mutant library, since a pair of outer primers contain a sequence matching the anchor point sequence, the template DNA does not contain a sequence matching the anchor point sequence. sequence, therefore, template DNA does not amplify.
所述直接向构建单链突变体文库的反应体系中添加特异结合单链突变体的引物,边PCR获得单链突变体,边进行双链化反应和双链突变体的扩增反应的一步PCR中,将上、下游锚点引物、编辑引物与模板DNA以适当摩尔比混合,同时,分别加入2-5倍锚点引物量的上、下游外端引物,添加DNA聚合酶、DNA连接酶和反应缓冲液。反应缓冲液中Mg2+浓度为1-10mM,PCR退火温度为40-66℃,PCR延伸温度为65-72℃,PCR反应循环数为1-35个。PCR产物大量的双链突变体文库,及极少量的模板DNA。The one-step PCR of directly adding primers that specifically bind to single-stranded mutants to the reaction system for constructing a single-stranded mutant library, obtaining single-stranded mutants by PCR, and performing double-stranded reaction and amplification reaction of double-stranded mutants In the method, mix the upstream and downstream anchor primers, editing primers and template DNA at an appropriate molar ratio, and at the same time, add 2-5 times the amount of the anchor primer, the upstream and downstream outer primers, add DNA polymerase, DNA ligase and Reaction buffer. The Mg 2+ concentration in the reaction buffer is 1-10mM, the PCR annealing temperature is 40-66°C, the PCR extension temperature is 65-72°C, and the number of PCR reaction cycles is 1-35. A large number of double-stranded mutant libraries of PCR products, and a very small amount of template DNA.
所述一步PCR的退火过程中,为避免锚点引物与外端引物的结合,锚点引物中锚点序列的长度约占锚点引物长度的三分之一。During the annealing process of the one-step PCR, in order to avoid the combination of the anchor primer and the outer primer, the length of the anchor sequence in the anchor primer accounts for about one-third of the length of the anchor primer.
所述一步PCR中,上(下)游锚点引物长度可以为60bp,其中40bp与亲本模板完全匹配,还有20bp的锚点序列;上(下)游外端引物长度为20bp,与锚点序列相同或互补。In the one-step PCR, the length of the upstream (downstream) anchor primer can be 60bp, of which 40bp is completely matched with the parental template, and there is also a 20bp anchor sequence; The sequences are identical or complementary.
所述一步PCR中,上(下)游锚点引物和上(下)游外端引物的添加比例可以为1:(2-5),过量的上(下)游外端引物能使生成的单链突变体完全双链化成双链突变体。In the one-step PCR, the addition ratio of the upstream (downstream) anchor primer and the upstream (downstream) outer primer can be 1: (2-5), and the excess upstream (downstream) outer primer can make the generated Single-stranded mutants are fully duplexed to double-stranded mutants.
在本发明的一种实施方式中,采用的DNA聚合酶为高保真的耐热DNA聚合酶,优选5’-3’外切酶活性缺失的高保真DNA聚合酶,如Phusion DNA polymerase(NEB)。In one embodiment of the present invention, the DNA polymerase used is a high-fidelity thermostable DNA polymerase, preferably a high-fidelity DNA polymerase whose 5'-3' exonuclease activity is missing, such as Phusion DNA polymerase (NEB) .
在本发明的一种实施方式中,采用的DNA连接酶为耐热DNA连接酶,如Taq DNA ligase(NEB)、9N DNA ligase(NEB)和Ampligase(EPI),优选Ampligase。In one embodiment of the present invention, the DNA ligase used is a thermostable DNA ligase, such as Taq DNA ligase (NEB), 9N DNA ligase (NEB) and Ampligase (EPI), preferably Ampligase.
为筛选突变体,可将突变体文库与载体同体外组装技术进行整合。To screen mutants, mutant libraries and vectors can be integrated with in vitro assembly techniques.
所述的体外组装技术可以为融合PCR、Gibson组装、T4DNA聚合酶介导的重组技术或者体内酵母组装技术。Gibson组装技术的原理为在组装反应体系中,T5核酸外切酶能从双链DNA片段的5’端往里进行切割,产生3’端突出的黏性末端,由于各个片段之间具有同源臂序列,相邻近的两个完全互补配对的黏性末端片段发生结合,产生的缺口由DNA聚合酶补平和Taq DNA连接酶连接完成,从而实现重组片段的无缝组装。The in vitro assembly technology may be fusion PCR, Gibson assembly, T4 DNA polymerase-mediated recombination technology or in vivo yeast assembly technology. The principle of Gibson assembly technology is that in the assembly reaction system, T5 exonuclease can cut from the 5' end of the double-stranded DNA fragment to produce a sticky end protruding from the 3' end. Arm sequence, two adjacent completely complementary cohesive end fragments are combined, and the resulting gap is filled by DNA polymerase and ligated by Taq DNA ligase, so as to realize the seamless assembly of recombinant fragments.
图1可以帮助理解本发明的原理,图1不代表本发明的唯一实施方式。本发明主要包括分别采用不同引物进行的两轮PCR以及对第二轮PCR产物进行筛选的过程。第一轮PCR涉及图1上端显示的5条5’至3’方向的引物,其中带有虚线的两条引物为锚点引物,虚线所示部分即为锚点序列,分别带有★、▲、◆的为针对不同目标突变区域设计的编辑引物;在PCR过程的变性阶段,亲本DNA解链得到两条单链DNA,由于5条引物都只能与3’至5’方向的DNA链结合,因此,整个PCR过程中只有3’至5’方向的亲本DNA链能作为模板链,相应地,这一轮PCR结束后会得到大量5’至3’方向的单链突变体、少量未被用作模板的单链DNA、少量与模板结合着的处于双链状态的发生突变的DNA链。以第一轮PCR混合产物作为模板,或采用DNA溶液柱纯方式回收单链突变体作为模板,以减少其它影响因素。相应地,第二轮PCR可以不更换反应体系,直接向第一轮PCR混合产物中加入上、下游外端引物,或者重新配制PCR反应体系。第二轮PCR涉及一对外端引物,该外端引物与第一轮PCR中的锚点引物的锚点序列匹配或相同,因此该外端引物只与带有锚点序列的单链DNA结合进行扩增反应,而亲本DNA由于缺少能与锚点序列匹配的序列而得不到扩增。最后,通过对丰富的双链突变体库进行筛选获取理想的突变体。Fig. 1 can help to understand the principle of the present invention, and Fig. 1 does not represent the only embodiment of the present invention. The present invention mainly includes two rounds of PCR respectively using different primers and the process of screening the second round of PCR products. The first round of PCR involves five primers in the 5' to 3' direction shown at the top of Figure 1, among which the two primers with dotted lines are anchor primers, and the part indicated by the dotted line is the anchor sequence, marked with ★, ▲ , ◆ are editing primers designed for different target mutation regions; during the denaturation stage of the PCR process, the parental DNA melts to obtain two single-stranded DNAs, since the five primers can only combine with the DNA strand in the 3' to 5' direction Therefore, only the parental DNA strand in the 3' to 5' direction can be used as the template strand during the entire PCR process. Single-stranded DNA used as a template, and a small amount of mutated DNA strand in a double-stranded state bound to the template. Use the mixed product of the first round of PCR as a template, or recover the single-stranded mutant as a template by using DNA solution column purification method to reduce other influencing factors. Correspondingly, the second round of PCR may not change the reaction system, directly add the upstream and downstream outer end primers to the first round of PCR mixed product, or reconfigure the PCR reaction system. The second round of PCR involves a pair of outer primers that match or are identical to the anchor sequence of the anchor primer in the first round of PCR, so that the outer primers only bind to single-stranded DNA with the anchor sequence Amplification reaction, while the parental DNA is not amplified due to the lack of a sequence that matches the anchor sequence. Finally, the ideal mutant is obtained by screening the abundant double-stranded mutant library.
图4为在图1的基础上进行简化后得到的一步PCR,能直接制备双链突变体文库。一步PCR是在第一轮PCR反应体系中就添加了上、下游外端引物,这样,在反应的过程中,新生成的单链突变体与上游或下游外端引物结合,并扩增形成双链突变体,而亲本链由于不能和外端引物结合,不会被扩增。在此过程中,形成的突变体以指数的形式增长,相比两轮PCR反应体系,产生的突变体更多。同时,在操作上更加方便,耗时短。Fig. 4 is a simplified one-step PCR obtained on the basis of Fig. 1, which can directly prepare a double-stranded mutant library. One-step PCR is to add the upper and lower outer end primers in the first round of PCR reaction system, so that during the reaction process, the newly generated single-stranded mutants are combined with the upstream or downstream outer end primers and amplified to form double-stranded mutants. chain mutants, and the parental chain will not be amplified because it cannot bind to the outer primer. During this process, the mutants formed grow exponentially, and more mutants are produced than in the two-round PCR reaction system. At the same time, it is more convenient and time-consuming in operation.
本发明以体外PCR重组技术为基础,人工合成单链突变体文库,通过设计针对多个目标区域的编辑引物,PCR后获得含有多样性极其丰富的突变文库,双链化后再采用体外重组技术构建突变体筛选文库。本发明克服了现有随机突变多样性不足、DNA shuffling技术受同源序列和同源基因材料限制的缺点,而且操作实施简单,易于获得丰富的突变体文库,为基因体外快速进化奠定了基础。用于快速高效进化的对象包括启动子、核糖体结合位点、非转录翻译调控区等多个DNA序列。Based on the in vitro PCR recombination technology, the present invention artificially synthesizes a single-stranded mutant library. By designing editing primers for multiple target regions, a mutant library with extremely rich diversity is obtained after PCR, and the in vitro recombination technology is used after double-stranding Construction of mutant screening libraries. The present invention overcomes the disadvantages of lack of diversity in existing random mutations, and DNA shuffling technology is limited by homologous sequences and homologous gene materials, and is easy to operate and implement, and is easy to obtain abundant mutant libraries, laying the foundation for the rapid evolution of genes in vitro. Objects for rapid and efficient evolution include multiple DNA sequences such as promoters, ribosome binding sites, and non-transcribed translational regulatory regions.
附图说明Description of drawings
图1所示为合成单链DNA文库快速组合进化酶和代谢途径的方法示意图;两端虚线位置为锚点序列。Figure 1 is a schematic diagram of the method for the rapid combinatorial evolution of enzymes and metabolic pathways by synthesizing a single-stranded DNA library; the dotted lines at both ends are anchor sequences.
图2所示为突变体文库中各突变体单位菌体的荧光强度示意图,箭头所指为野生型启动子的单位荧光强度值。Figure 2 is a schematic diagram of the fluorescence intensity of each mutant unit cell in the mutant library, and the arrow indicates the unit fluorescence intensity value of the wild-type promoter.
图3所示为不同强度的突变启动子rpoS突变序列比对示意图。Fig. 3 is a schematic diagram showing the sequence alignment of rpoS mutant promoters with different strengths.
图4所示为RECODE技术采用一步PCR反应系统组合进化DNA的方法示意图;两端虚线位置为锚点序列。Fig. 4 is a schematic diagram of a method for combining and evolving DNA using a one-step PCR reaction system in RECODE technology; the dotted lines at both ends are anchor point sequences.
具体实施方式Detailed ways
实施例1应用一步PCR对大肠杆菌rpoS基因的组成型启动子进行体外改造Example 1 Application of one-step PCR to transform the constitutive promoter of E. coli rpoS gene in vitro
以大肠杆菌rpoS基因的组成型启动子为例,核苷酸序列如SEQ ID NO.1所示,对其内部4个-10和-35区间的间隔序列同时进行组合突变,构建突变体文库。分别根据启动子区段序列设计4条编辑引物,编辑引物(Jps/rpoSp-F、Jps/rpoSp4-F、Jps/rpoSp3-F、Jps/rpoSp21-F)、锚点引物(Jps/rpoSp-HM-F、Jps/rpoSp-HM-R)外端引物(rpoSp-F、rpoSp-R)和载体制备引物分别如下所示:Taking the constitutive promoter of the rpoS gene of Escherichia coli as an example, the nucleotide sequence is shown in SEQ ID NO.1, and the four internal spacer sequences of -10 and -35 intervals were combined and mutated at the same time to construct a mutant library. Four editing primers were designed according to the sequence of the promoter segment, editing primers (Jps/rpoSp-F, Jps/rpoSp4-F, Jps/rpoSp3-F, Jps/rpoSp21-F), anchor primers (Jps/rpoSp-HM -F, Jps/rpoSp-HM-R) outer primers (rpoSp-F, rpoSp-R) and vector preparation primers are as follows:
Jps/rpoSp-F:TTCCACCGTTGCTGTTGCGTNNNNNNNNNNNNNNNNNTATTCTGAGTCTTCGGGTGAACJps/rpoSp-F:TTCCACCGTTGCTGTTGCGTNNNNNNNNNNNNNNNNTATTCTGAGTCTTCGGGTGAAC
Jps/rpoSp4-F:CATAACGACACAATGCTGGTNNNNNNNNNNNNNNAAGTTAAGGCGGGGCAAAAAATAGCJps/rpoSp4-F:CATAACGACACAATGCTGGTNNNNNNNNNNNNNAAGTTAAGGCGGGGCAAAAAATAGC
Jps/rpoSp3-F:TAGCACCGGAACCAGTTCAANNNNNNNNNNNNNNNNAATTCGTTACAAGGGGAAATCCGJps/rpoSp3-F:TAGCACCGGAACCAGTTCAANNNNNNNNNNNNNNNNAATTCGTTACAAGGGGAAATCCG
Jps/rpoSp21-F:GCAGCGATAAATCGGCGGAACNNNNNNNNNNNNNNNNTGNTCCGTCAAGGGATCACGGGJps/rpoSp21-F:GCAGCGATAAATCGGCGGAACNNNNNNNNNNNNNNNNNTGNTCCGTCAAGGGATCACGGG
Jps/rpoSp-HM-F:CACTATAGGGCGAATTGGAGCTCCATACGCGCTGAACGTTGGTCAGJps/rpoSp-HM-F:CACTATAGGGCGAATTGGAGCTCCATACGCGCTGAACGTTGGTCAG
Jps/rpoSp-HM-R:TCAAGGGATCACGGGTAGGAGCCACCGATCCATGGGTAAGGGAGAAGAACJps/rpoSp-HM-R:TCAAGGGATCACGGGTAGGAGCCACCGATCCATGGGTAAGGGAGAAGAAC
rpoSp-F:CACTATAGGGCGAATTGGAGCTrpoSp-F:CACTATAGGGCGAATTGGAGCT
rpoSp-R:GTTCTTCTCCCTTACCCATGGATCrpoSp-R:GTTCTTCTCCCCTTACCCATGGATC
PBBR2-gfp-F:CCATGGGTAAGGGAGAAGAACPBBR2-gfp-F:CCATGGGTAAGGGAGAAGAAC
PBBR2-gfp-R:CCGGAATTCTTATTTGTATAGTTCATCCATGPBBR2-gfp-R:CCGGAATTCTTATTTGTATAGTTCATCCATG
两条锚点引物Jps/rpoSp-HM-F和Jps/rpoSp-HM-R与编辑引物为同方向,且都与同一单链模板配对,锚点引物带有20多bp的锚点序列,锚点序列与载体pBBRMCS2-gfp的缺口位置序列一致,用于同源重组克隆使用。克隆载体采用PBBR2-gfp-F和PBBR2-gfp-R引物扩增,突变启动子插入位置位于绿色荧光蛋白gfp上游,用于驱动gfp蛋白表达,通过报告基因gfp的荧光强度来检测启动子的强弱。首先将编辑引物Jps/rpoSp-F、Jps/rpoSp4-F、Jps/rpoSp3-F、Jps/rpoSp21-F和下游锚点引物Jps/rpoSp-HM-R等摩尔比混合,采用T4多聚核苷酸激酶进行磷酸化反应,反应体系按商品说明书进行操作,37℃反应30min,70℃10min失活酶。The two anchor primers Jps/rpoSp-HM-F and Jps/rpoSp-HM-R are in the same direction as the editing primers, and both are paired with the same single-stranded template. The anchor primers have an anchor sequence of more than 20 bp, and the anchor The point sequence is consistent with the gap position sequence of the vector pBBRMCS2-gfp, which is used for homologous recombination cloning. The cloning vector was amplified with PBBR2-gfp-F and PBBR2-gfp-R primers. The insertion position of the mutant promoter was located upstream of the green fluorescent protein gfp, which was used to drive the expression of GFP protein. The intensity of the promoter was detected by the fluorescence intensity of the reporter gene GFP. weak. First, the editing primers Jps/rpoSp-F, Jps/rpoSp4-F, Jps/rpoSp3-F, Jps/rpoSp21-F and the downstream anchor primer Jps/rpoSp-HM-R were mixed in an equimolar ratio, using T4 polynucleoside The phosphorylation reaction of acid kinase was carried out, and the reaction system was operated according to the product instructions, and the reaction was carried out at 37°C for 30 minutes, and at 70°C for 10 minutes to inactivate the enzyme.
制备单链突变体文库为PCR循环的DNA延伸和连接同步的反应。在25μl反应体系中:2.5μl 10x反应缓冲液,上游锚点引物Jps/rpoSp-HM-F、磷酸化的下游锚点引物和磷酸化的编辑引物适量(根据磷酸化体系计算,每条编辑引物1pmol),DNA模板加入量约1-5ng(与引物比例为1:100),加入Phusion DNA polymerase(NEB)0.5μl,Ampligase(EPI)连接酶1μl。混匀后按如下PCR程序运行:94℃2min,[94℃30s,50℃1min,66℃5min]x25,72℃5min,4℃hold on。第一轮PCR产物为单链突变体文库,可立即进行下一步实验,或者-20℃保存。Preparation of single-stranded mutant libraries is a simultaneous reaction of PCR cycles for DNA extension and ligation. In a 25 μl reaction system: 2.5 μl 10x reaction buffer, upstream anchor primer Jps/rpoSp-HM-F, phosphorylated downstream anchor primer and phosphorylated editing primer (calculated according to the phosphorylation system, each editing primer 1pmol), the amount of DNA template added is about 1-5ng (the ratio of primer to primer is 1:100), Phusion DNA polymerase (NEB) 0.5μl, Ampligase (EPI) ligase 1μl are added. After mixing, run according to the following PCR program: 94°C for 2min, [94°C for 30s, 50°C for 1min, 66°C for 5min] x25, 72°C for 5min, 4°C hold on. The first-round PCR product is a single-stranded mutant library, which can be used for the next step immediately or stored at -20°C.
双链突变文库的制备:第二轮PCR用于制备全长完整基因,在50μl反应体系中,25μl 2x预混DNA聚合酶(Superpfu mix,杭州宝赛生物科技有限公司),全长基因两端的外端引物rpoSp-F和rpoSp-R各1μl(10μM),上述步骤中制备的单链反应液5μl做模板,按下述PCR程序扩增:94℃3min,[94℃30s,55℃30min,68℃1min]x32,72℃5min,4℃hold on。PCR产物以1%琼脂糖凝胶电泳切胶回收。采用凝胶回收试剂盒按说明书推荐方法回收PCR产物。Preparation of double-stranded mutant library: The second round of PCR is used to prepare the full-length complete gene. In a 50 μl reaction system, 25 μl 2x premixed DNA polymerase (Superpfu mix, Hangzhou Baosai Biotechnology Co., Ltd.), and the two ends of the full-length gene 1 μl (10 μM) of each of the outer primers rpoSp-F and rpoSp-R, and 5 μl of the single-strand reaction solution prepared in the above steps as a template, amplified according to the following PCR program: 94°C for 3 minutes, [94°C for 30 seconds, 55°C for 30 minutes, 68°C 1min] x32, 72°C 5min, 4°C hold on. PCR products were recovered by 1% agarose gel electrophoresis. The PCR product was recovered using the gel recovery kit according to the method recommended in the manual.
突变文库与载体的组装采用Gibson组装技术,Gibson组装技术参照文献Daniel G Gibson.et al.2009.NATURE METHODS VOL.6NO.5 343-345。5×反应缓冲液配置:25%PEG-8000、500mM Tris-HCl pH 7.5、50mM MgCl2、50mM DTT,dNTPs各1mM以及5mM NAD。20μl反应体系中含有8μl5×反应缓冲液,0.8μl T5exonuclease(0.2U/μl Epicentre),4μl TaqDNA ligase(40U/μl New England Biolabs(NEB))和0.5μl Phusion DNA polymerase(2U/μlNEB)。同时,线性化载体加入50ng,突变文库片段与载体等摩尔比的量。反应体系混匀后50℃反应60min。全部反应液转化大肠杆菌感受态细胞,按正常转化步骤操作,37℃后培养1h后,全部涂布含50μg/ml卡纳青霉素的LB平板,倒置37℃培养过夜。The assembly of the mutant library and the vector adopts the Gibson assembly technology. The Gibson assembly technology refers to the literature Daniel G Gibson.et al.2009.NATURE METHODS VOL.6NO.5 343-345. 5×reaction buffer configuration: 25% PEG-8000, 500mM Tris-HCl pH 7.5, 50 mM MgCl 2 , 50 mM DTT, 1 mM each of dNTPs and 5 mM NAD. The 20 μl reaction system contained 8 μl 5× reaction buffer, 0.8 μl T5exonuclease (0.2U/μl Epicentre), 4 μl TaqDNA ligase (40U/μl New England Biolabs (NEB)) and 0.5 μl Phusion DNA polymerase (2U/μl NEB). At the same time, 50 ng of the linearized vector was added, and the amount of the mutant library fragment and the vector was in an equal molar ratio. After mixing the reaction system, react at 50°C for 60 minutes. All the reaction liquids were transformed into E. coli competent cells, and operated according to the normal transformation steps. After incubating at 37°C for 1 hour, all were coated with LB plates containing 50 μg/ml kanapenicillin, and incubated overnight at 37°C.
对长出的克隆进行高通量筛选,采用96孔板培养,随机挑取1000个单克隆接种于96孔板LB培养基中,添加50μg/ml卡纳青霉素,37培养24h。96孔板培养液进行3500rpm离心5min,采用无菌水反复洗涤3遍,去除培养基的影响,加入适量的无菌水重悬后,采用酶标仪进行荧光强度和菌体OD600值的扫描。根据单位菌体的荧光强度来表示突变启动子的强弱,结果如附图2所示,突变文库中启动子的强度变化幅度范围在6%-460%之间,由此说明本发明方法对启动子的体外高效组合进化具有明显的效果。同时,测序结果分析如图3所示,产生的不同强度的突变启动子,其序列突变多样性变化显著,在4个启动子的间隔区域,引入的突变碱基达到10-20个之多,且每个位点引入的突变碱基均不相同。High-throughput screening was performed on the grown clones, cultured in a 96-well plate, and 1000 single clones were randomly selected and inoculated in LB medium of a 96-well plate, added with 50 μg/ml kanapenicillin, and cultured for 24 hours at 37 hours. The 96-well plate culture solution was centrifuged at 3500rpm for 5 minutes, washed repeatedly with sterile water for 3 times to remove the influence of the medium, added an appropriate amount of sterile water to resuspend, and used a microplate reader to scan the fluorescence intensity and cell OD 600 value . The strength of the mutant promoter is represented according to the fluorescence intensity of the unit thalline, and the result is shown in Figure 2, the intensity variation range of the promoter in the mutant library is between 6%-460%, thus illustrating that the method of the present invention is effective Efficient combinatorial evolution of promoters in vitro has obvious effects. At the same time, the analysis of the sequencing results is shown in Figure 3. The mutant promoters of different strengths generated have a significant change in sequence mutation diversity. In the interval region between the four promoters, as many as 10-20 mutant bases were introduced. And the mutated bases introduced at each site are different.
虽然本发明已以较佳实施例公开如上,但其并非用以限定本发明,任何熟悉此技术的人,在不脱离本发明的精神和范围内,都可做各种的改动与修饰,因此本发明的保护范围应该以权利要求书所界定的为准。Although the present invention has been disclosed above with preferred embodiments, it is not intended to limit the present invention. Any person familiar with this technology can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore The scope of protection of the present invention should be defined by the claims.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510212921.9A CN104789555A (en) | 2015-04-29 | 2015-04-29 | Method of expressing regulatory element based on evolution gene by synthesizing single-chain DNA library |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510212921.9A CN104789555A (en) | 2015-04-29 | 2015-04-29 | Method of expressing regulatory element based on evolution gene by synthesizing single-chain DNA library |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104789555A true CN104789555A (en) | 2015-07-22 |
Family
ID=53554749
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510212921.9A Pending CN104789555A (en) | 2015-04-29 | 2015-04-29 | Method of expressing regulatory element based on evolution gene by synthesizing single-chain DNA library |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104789555A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104805508A (en) * | 2015-04-29 | 2015-07-29 | 江南大学 | Method for evolving metabolic pathways based on synthetic single-stranded DNA library |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0812918A2 (en) * | 1996-06-11 | 1997-12-17 | Institut Pasteur | Method of selection of allelic exchange mutants |
WO2003099999A2 (en) * | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
WO2005121351A2 (en) * | 2004-05-27 | 2005-12-22 | Novozymes, Inc. | Methods for transforming and expression screening of filamentous fungal cells with a dna library |
WO2007017229A2 (en) * | 2005-08-08 | 2007-02-15 | Geneart Ag | Method for carrying out the selective evolution of proteins in vitro |
CN101302559A (en) * | 2008-06-03 | 2008-11-12 | 湖北大学 | A Rapid Plasmid Rescue Method for Screening Directed Evolution Mutant Enzymes |
CN101484462A (en) * | 2006-07-05 | 2009-07-15 | 斯克利普斯研究院 | Chimeric zinc finger recombinases optimized for catalysis by directed evolution |
CN104789556A (en) * | 2015-04-29 | 2015-07-22 | 江南大学 | Method of carrying out rapid and efficient DNA combination and evolution based on synthesis of single-chain DNA library |
CN104805508A (en) * | 2015-04-29 | 2015-07-29 | 江南大学 | Method for evolving metabolic pathways based on synthetic single-stranded DNA library |
-
2015
- 2015-04-29 CN CN201510212921.9A patent/CN104789555A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0812918A2 (en) * | 1996-06-11 | 1997-12-17 | Institut Pasteur | Method of selection of allelic exchange mutants |
WO2003099999A2 (en) * | 2002-05-20 | 2003-12-04 | Abmaxis, Inc. | Generation and selection of protein library in silico |
WO2005121351A2 (en) * | 2004-05-27 | 2005-12-22 | Novozymes, Inc. | Methods for transforming and expression screening of filamentous fungal cells with a dna library |
WO2007017229A2 (en) * | 2005-08-08 | 2007-02-15 | Geneart Ag | Method for carrying out the selective evolution of proteins in vitro |
CN101484462A (en) * | 2006-07-05 | 2009-07-15 | 斯克利普斯研究院 | Chimeric zinc finger recombinases optimized for catalysis by directed evolution |
CN101302559A (en) * | 2008-06-03 | 2008-11-12 | 湖北大学 | A Rapid Plasmid Rescue Method for Screening Directed Evolution Mutant Enzymes |
CN104789556A (en) * | 2015-04-29 | 2015-07-22 | 江南大学 | Method of carrying out rapid and efficient DNA combination and evolution based on synthesis of single-chain DNA library |
CN104805508A (en) * | 2015-04-29 | 2015-07-29 | 江南大学 | Method for evolving metabolic pathways based on synthetic single-stranded DNA library |
Non-Patent Citations (2)
Title |
---|
ANDREAS SEYFANG AND JEAN HUAQIAN JIN: "Multiple site-directed mutagenesis of more than 10 sites simultaneously and in a single round", 《ANALYTICAL BIOCHEMISTRY 》 * |
刘志国: "《基因工程原理与技术》", 31 January 2011 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104805508A (en) * | 2015-04-29 | 2015-07-29 | 江南大学 | Method for evolving metabolic pathways based on synthetic single-stranded DNA library |
CN104805508B (en) * | 2015-04-29 | 2017-07-14 | 江南大学 | A kind of method based on synthesizing single-stranded DNA library evolution metabolic pathway |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11078498B2 (en) | CRISPR enabled multiplexed genome engineering | |
CA2715586C (en) | Methods for in vitro joining and combinatorial assembly of nucleic acid molecules | |
CN104789556A (en) | Method of carrying out rapid and efficient DNA combination and evolution based on synthesis of single-chain DNA library | |
CN104877977A (en) | Method for evolving enzyme based on synthetic single-stranded DNA (deoxyribonucleic acid) library | |
CN104593354A (en) | Method for rapid directed evolution of DNA on basis of in vitro combined assembly | |
Lee et al. | Cytosine base editing in cyanobacteria by repressing archaic Type IV uracil‐DNA glycosylase | |
CN104805508B (en) | A kind of method based on synthesizing single-stranded DNA library evolution metabolic pathway | |
CN104789555A (en) | Method of expressing regulatory element based on evolution gene by synthesizing single-chain DNA library | |
US9416359B2 (en) | Method for constructing mutagenesis libraries in situ | |
Tee et al. | Back to basics: Creating genetic diversity | |
van den Brink et al. | MOSAIC: a highly efficient, one-step recombineering approach to plasmid editing and diversification | |
CN117778377B (en) | Large-fragment DNA efficient synthesis and assembly method based on novel programmable nuclease Argonaute | |
Poluri et al. | Expanding the synthetic protein universe by guided evolutionary concepts | |
Kagami et al. | Effective DNA shuffling methods for enzyme evolution | |
Pera et al. | Hybrid enzymes | |
KR20060126570A (en) | Generation of recombinant genes in prokaryotic cells by the use of two extrachromosomal factors | |
van den Brink et al. | MANUSCRIPT TITLE | |
US20090305359A1 (en) | Method for producing circular duplex polynucleotides from linear duplex polynucleotides and applications thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150722 |
|
RJ01 | Rejection of invention patent application after publication |